000			03572cam a2200349 a 4500
003			EG-GiCUC
005			20250223031609.0
008			161106s2016 ua h f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aPh.D
099			_aCai01.19.05.Ph.D.2016.Ah.C
100	0		_aAhmed Hussein Algammal
245	1	0	_aCOX-2 expression as a prognostic factor in pediatric hodgkin lymphoma / _cAhmed Hussein Algammal ; Supervised Lobna Mohamed Alamin Shalaby , Mohamed Fawzy Ibrahim Hasan , Asmaa Ibrahim Abdelaziz Salama
246	1	5	_aدلالة الكوكس-٢ و أهميته المنزرة فى الأطفال المصابين بسرطان هودجكين الليمفاوى
260			_aCairo : _bAhmed Hussein Algammal , _c2016
300			_a162 P. : _bfacsimiles ; _c25cm
502			_aThesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Pediatric Oncology
520			_aBackground: Cyclooxygenase 2 (COX-2) is an inflammatory enzyme and it was proved to have a role in tumorigenesis mechanisms including tumor proliferation, differentiation, immunosupression, angiogenesis and inhibition of apoptosis. It has been demonstrated that COX-2 expression increases in colon, stomach, esophagus, lung, ovary, cervix, liver, pancreas adenocarcinomas and brain tumors as a negative prognostic parameter. Methods: We investigated the prognostic value of COX-2 expression using immunstaining in a group of pediatric Hodgkin lymphoma (HL) patients (n=131), who presented during the period from January 2005 till June 2013, and whose data were retrieved from the medical record of the Pediatric Oncology department, National Cancer Institute, Cairo University and they were followed up till August 2015. Statistical analysis was done, including comparing the most recognized clinical variables in relation to COX-2 expression. Results: Cyclooxygenase 2 was expressed on Reed-Sternberg cells in 37.4% of the whole group. There were no differences in the distribution of prognostic variables according to COX-2 expression. With a mean follow-up period of 54.4 months, 5 year PFS was lower in COX-2+ve than that in COX-2 -ve patients but without statistical significance. The 5 year overall survival was also lower in COX-2 +ve patients than in {u2013}ve ones without statistical significance as well. The major impact on prognosis was observed in male group of patients. With a significantly worse 5 year OS (82.9) in +ve % compared to 100% in COX-2 {u2013}ve patients (P value: 0.045) and tendency for Abstract 2 statistical significant 5 year PFS (75.7% Vs 90.2%) in +ve and {u2013}ve respectively (P value: 0.06). Conclusion: COX-2 was expressed on Reed-Sternberg cells in about one third of HL patients and found to be an unfavorable prognostic factor in males with HL. We conclude that COX-2 is a negative prognostic variable in male HL and might be therapeutic target. However, further studies including larger numbers of HL patients are needed to investigate that COX-2 may be a major prognostic variable in HL. expression.
530			_aIssued also as CD
653		4	_aCyclooxygenase 2
653		4	_aPediatric hodgkin lymphoma
653		4	_aPrognostic factors
700	0		_aAsmaa Ibrahim Abdelaziz Salama , _eSupervisor
700	0		_aLobna Mohamed Alamin Shalaby , _eSupervisor
700	0		_aMohamed Fawzy Ibrahim Hasan , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aSamia _eCataloger
942			_2ddc _cTH
999			_c58465 _d58465